UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 25, 2023
Longboard Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
| | |
Delaware | 1-40192 | 84-5009619 |
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | |
4275 Executive Square, Suite 950 La Jolla, CA |
| 92037 |
(Address of Principal Executive Offices) |
| (Zip Code) |
Registrant’s Telephone Number, Including Area Code: (858) 789-9283
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| |
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | |
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Common stock, par value $0.0001 per share | | LBPH | | The Nasdaq Global Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
In this report, “we” and “our” refer to Longboard Pharmaceuticals, Inc.
Item 5.07 Submission of Matters to a Vote of Security Holders.
We held our 2023 Annual Stockholders' Meeting (the “Annual Meeting”) on May 25, 2023. At the Annual Meeting, our stockholders:
(i)Elected three Class II directors named herein to hold office until our 2026 Annual Stockholders' Meeting.
(ii)Ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023.
The tables below set forth the results of the vote of our stockholders for the Annual Meeting.
Proposal 1: The election of three Class II directors
| | | |
Director Nominee | For | Withheld | Broker Non-Votes |
Vincent E. Aurentz | 14,728,717 | 2,922,032 | 1,978,804 |
Casey C. Lynch | 13,117,562 | 4,533,187 | 1,978,804 |
Jane Tiller, MBChB, FRCPsych | 13,117,582 | 4,533,167 | 1,978,804 |
Proposal 2: The ratification of the selection of KPMG LLP
| |
Votes for approval | 19,617,556 |
Votes against approval | 474 |
Abstentions | 11,523 |
Broker non-votes | N/A |
Item 9.01 Financial Statements and Exhibits. (d) Exhibits.
| |
Exhibit No. | Description |
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | |
|
| Longboard Pharmaceuticals, Inc. |
|
|
|
|
Date: May 26, 2023 |
| By: | /s/ Kevin R. Lind |
|
|
| Kevin R. Lind |
|
|
| President and Chief Executive Officer |
